Skip to main content
Clinical Trials/NCT04570163
NCT04570163
Recruiting
N/A

Berlin Registry of Right Heart Interventions

Charite University, Berlin, Germany1 site in 1 country200 target enrollmentJune 16, 2020

Overview

Phase
N/A
Intervention
Not specified
Conditions
Tricuspid Regurgitation
Sponsor
Charite University, Berlin, Germany
Enrollment
200
Locations
1
Primary Endpoint
Overall mortality
Status
Recruiting
Last Updated
last month

Overview

Brief Summary

The present study evaluates patients after interventional therapy of valvular diseases of the right heart. Follow-up examinations include medical history taking, laboratory measurements and an echo. The aim is to assess the different interventional therapies and their impact on patient's outcome.

Detailed Description

The subject of the study is to register interventional therapies of right heart diseases (such as "cardioband" and "edge-to-edge" techniques of the tricuspid valve) performed in Berlin/ Brandenburg (primarily at the Charité, Universitätsmedizin Berlin). Based on the development and the increasing use of interventional therapies in tricuspid and pulmonary valve diseases, the impact on the patients' symptoms and life expectancy after interventions will be investigated. The aim is to identify patient subgroups that benefit the most. Primary endpoints: Total mortality, cardiovascular mortality, heart failure hospitalization. Secondary endpoints: NYHA class, NTproBNP, liver and kidney function (laboratory measurements), valve function, cardiac function, and cardiac morphology.

Registry
clinicaltrials.gov
Start Date
June 16, 2020
End Date
December 31, 2035
Last Updated
last month
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Prof. Dr. Henryk Dreger

Professor

Charite University, Berlin, Germany

Eligibility Criteria

Inclusion Criteria

  • Patients with planned or recent valve interventions of the right heart (tricuspid regurgitation/ stenosis, pulmonary regurgitation/ stenosis)
  • \>18 years
  • Written, documented consent

Exclusion Criteria

  • Patients in care or unable to consent
  • Patients who are unable to comply with follow-up examinations
  • Patients who are detained in an institution

Outcomes

Primary Outcomes

Overall mortality

Time Frame: 2 months after intervention

Number of deceased participants after 2 months after intervention

Cardiovascular mortality

Time Frame: 2 months after intervention

Number of deceased participants after 2 months after intervention (cardiovascular cause of mortality)

Unscheduled hospitalization for heart failure progression

Time Frame: 2 months after intervention

Number of participants with unscheduled hospitalization for heart failure progression after 2 months after intervention

Secondary Outcomes

  • valve function(2 months after intervention)
  • NYHA class(2 months after intervention)
  • liver function(2 months after intervention)
  • cardiac function(2 months after intervention)
  • NTproBNP(2 months after intervention)
  • kidney function(2 months after intervention)
  • cardiac morphology(2 months after intervention)

Study Sites (1)

Loading locations...

Similar Trials